KLK3 and pachyonychia congenita: In a previous analysis of this prospective biomarker trial we demonstrated the diagnostic and prognostic superiority of molecular LN staging using expression of the prostate-specific gene KLK3 as compared to conventional histopathology for detection of LN metastasis in PC patients undergoing RP with ePLND for intermediate and high-risk PC [18].